Lyra Therapeutics, Inc.

LYRA · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$22,055$29,784$31,735$40,577
Short-Term Investments$0$0$0$0
Receivables$0$0$0$0
Inventory$0$0$0$0
Other Curr. Assets$964$1,279$2,170$2,448
Total Curr. Assets$23,019$31,063$33,905$43,025
Property Plant & Equip (Net)$18,697$19,517$20,418$21,328
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$1,993$1,993
Tax Assets$0$0$0$0
Other NC Assets$1,993$1,993$0$0
Total NC Assets$20,690$21,510$22,411$23,321
Other Assets$0$0$0$0
Total Assets$43,709$52,573$56,316$66,346
Liabilities
Payables$627$680$725$1,179
Short-Term Debt$4,684$0$0$0
Tax Payable$0$0$0$0
Deferred Revenue$7$32$216$398
Other Curr. Liab.$4,162$3,486$4,039$4,822
Total Curr. Liab.$9,480$11,163$11,470$12,631
LT Debt$26,695$0$0$0
Deferred Rev, NC$0$11,862$11,861$11,862
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$11,862$0$0$0
Total NC Liab.$38,557$39,788$40,974$42,121
Other Liabilities$0$0$0$0
Cap. Leases$31,379$32,478$33,356$34,380
Total Liabilities$48,037$50,951$52,444$54,752
Equity
Pref Stock$0$0$0$0
Common Stock$2$2$66$65
Retained Earnings-$426,758-$420,774-$413,337-$404,790
AOCI$0$0$0$0
Other Equity$422,428$0$0$0
Total Equity-$4,328$1,622$3,872$11,594
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$43,709$52,573$56,316$66,346
Net Debt$9,324-$29,784-$31,735-$40,577